Company news
Precigen, Inc. news in 2025
Precigen, Inc.'s news releases, calls and decks from 2025, newest first.
Precigen Reports Third Quarter 2025 Financial Results and Business Updates
November 12, 2025
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
November 5, 2025
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
October 12, 2025
EVERSANA Named by Precigen for U.S. Commercialization of PAPZIMEOS
September 11, 2025
Precigen Announces Up to $125 Million Non-Dilutive Financing
September 1, 2025
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
August 24, 2025
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
August 14, 2025
Precigen Reports First Quarter 2025 Financial Results and Business Updates
May 13, 2025
Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
April 15, 2025
Precigen Reports Full Year 2024 Financial Results and Business Updates
March 18, 2025
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
March 12, 2025
FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025
February 24, 2025
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
January 12, 2025
Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 8, 2025
Calls in 2025
Decks in 2025
- Corporate Update (August 2025)
Corporate update · 24 slides · Aug 18, 2025